MRKUSNASDAQ / NYSE · United States
MERCK & CO., INC. (MRK)
147.76USD+0.55%close 2026-11-13
Daily candles · 12 months
MRK · 1DPerformance
1W
+0.7%1M
+1.8%3M
+8.7%6M
+32.7%YTD
+40.4%1Y
+59.0%52W low 91.49high 156.92
-5.8% from the 52-week high.
Trend
- vs 20-day average
- Above by 0.9%
- vs 50-day average
- Above by 1.1%
- vs 200-day average
- Above by 14.9%
- ATR (14d)
- 2.83%
- 10-day range
- 7.2%
- Volume vs 20-day avg
- 0.66×
Position size
- Risk per share
- 6.27 USD
- Shares
- 15
- Position value
- 2,216.4 USD
- % of account
- 22.2%
- Risk amount
- 94.05 USD
- 1R target
- 154.03
- 2R target
- 160.30
- 3R target
- 166.57
Fundamentals and earnings
- Market cap
- 364.26B
- P/E (trailing)
- 147.8
- P/E (forward)
- 16.5
- EPS (TTM / next yr)
- 1.00 / 8.98
- Dividend yield
- 2.29%
- Earnings date
- Oct 29, 2026
Listing
- Ticker
- MRK US
- Yahoo / TradingView
- MRK · NASDAQ:MRK
- Keyword
- MRK
- Mapped to
- MERCK & CO., INC. (MRK)MRK US
Headlines
- Moderna Soars Another 9% as Piper Sandler Lifts Target to $305 on Raised OutlookTIKR · 5d ago
- INVA or MRK: Which Is the Better Value Stock Right Now?Zacks · 5d ago
- Global Arrayed CRISPR Screening Market Report 2026 | Capitalize on 17.7% CAGR to $3.43 Billion as Thermo Fisher, Merck, Agilent and GenScript Advance Precision Drug DiscoveryGlobeNewswire · 5d ago
- Will Bristol Myers' Growth Brands Offset Eliquis Headwinds?Zacks · 5d ago
- MRK's 2027 Outlook Challenging, Long-Term Prospects PromisingZacks · 5d ago
- What Happens To Pfizer Stock If Patent Losses Outpace New Drugs?Trefis · 5d ago
Prices and fundamentals from Yahoo Finance, delayed. Not financial advice.